Search results
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in...
FOX 23 News Albany· 4 hours agoUpon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 1 day agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda...
...Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in...
Morningstar· 17 hours agoThe VERSATILE-002 trial is evaluating Versamune® HPV (formerly PDS0101) in combination with the immune checkpoint...
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
InvestorPlace· 7 days agoIn the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoModerna stock surged — and then tumbled — in mid-April after the company unveiled early-stage test...
FDA approves bladder cancer treatment by Culver City company
LA Times via Yahoo News· 1 day agoIn an attempt to head off that surgery, doctors may consider another immunotherapy treatment....
...Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint...
WMBD - FOX 43 Peoria· 6 days agoUnder the terms of the agreement, GV20 will evaluate its lead investigational program GV20-0251, a first-in-class antibody targeting the novel immune checkpoint IGSF8, in combination with Merck's ...
Here’s Why Merck & Co. (MRK) Outperformed in Q1
Insider Monkey via Yahoo Finance· 18 hours agoBaron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be...
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Zacks via Yahoo Finance· 13 hours agoCorcept (CORT) reports positive data from the open-label portion of the phase III GRACE study...
US FDA approves ImmunityBio's bladder cancer therapy
Reuters via Yahoo News· 1 day ago(Reuters) -The U.S. health regulator approved on Monday ImmunityBio's combination therapy to treat a type of bladder cancer, marking an end to the...